Evidence map›Paper›PMID 32513235›Full record

ArticleJournal of experimental & clinical cancer research : CR2020

VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.

Jinbo Sun, Qisheng Tang, Yongheng Gao, Wei Zhang, Zhining Zhao, Fan Yang, Xiangnan Hu, Dan Zhang, Yong Wang, Huizhong Zhang and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. SALL4 Oncogenic Function in Cancers: Mechanisms and Therapeutic Relevance.International journal of molecular sciences · 2022
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Jinbo SunDepartment of Urology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China.
Qisheng TangDepartment of Urology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China.
Yongheng GaoDepartment of Respiratory and Critical Care Medicine, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China.
Wei ZhangDepartment of Urology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China.
Zhining ZhaoClinical Laboratory, The 986th Military Hospital, Fourth Military Medical University, Xi'an, 710054, Shaanxi, China.
Fan YangDepartment of Urology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China.
Xiangnan HuDepartment of Urology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China.
Dan ZhangDepartment of Pathology, Xi'an No. 3 Hospital, The Affiliated Hospital of Northwest University, Xi'an, 710018, Shaanxi, China.
Yong WangDepartment of Urology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China.
Huizhong ZhangMedical Laboratory and Research Center, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China.
Bin SongDepartment of Urology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China. songbinfmmu@126.com.
Bo ZhangDepartment of Urology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China. zhangbo@fmmu.edu.cn.
He WangDepartment of Urology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China. dusxjhw@fmmu.edu.cn.
Air Force Medical University · CNNorthwest University · CN

Funding

National Natural Science Foundation of China 81772745Science and Technology Research and Development Program of Shaanxi Province 2008K09-04-05
6 · The paper itself

Abstract

backgroundAlthough ongoing development of therapeutic strategies contributes to the improvements in clinical management, clear cell renal cell carcinoma (ccRCC) deaths originate mainly from radiochemoresistant and metastatic disease. Transcription factor SALL4 has been implicated in tumorigenesis and metastasis of multiple cancers. However, it is not known whether SALL4 is involved in the pathogenesis of ccRCC.

methodsAnalyses of clinical specimen and publicly available datasets were performed to determine the expression level and clinical significance of SALL4 in ccRCC. The influence of SALL4 expression on ccRCC tumor growth, metastasis and vascularity was evaluated through a series of in vitro and in vivo experiments. Western blotting, immunofluorescence staining and integrative database analysis were carried out to investigate the underlying mechanism for SALL4-mediated oncogenic activities in ccRCC.

resultsSALL4 expression was increased in ccRCC and positively correlated with tumor progression and poor prognosis. SALL4 could promote ccRCC cell proliferation, colony formation, cell cycle progression, migration, invasion and tumorigenicity and inhibit cell senescence. Further investigation revealed a widespread association of SALL4 with individual gene transcription and the involvement of SALL4 in endothelium development and vasculogenesis. In the context of ccRCC, SALL4 promoted tumor vascularization by recruiting endothelial cells. In addition, we found that SALL4 could exert its tumor-promoting effect via modulating Akt/GSK-3β axis and VEGFA expression. VHL mutation and DNA hypomethylation may be involved in the upregulation of SALL4 in ccRCC.

conclusionsOverall, our results provide evidence that upregulated SALL4 can function as a crucial regulator of tumor pathogenesis and progression in ccRCC, thus offering potential therapeutic strategies for future treatment.

Indexed as

MutationAnimalsApoptosisBiomarkers, TumorCarcinoma, Renal CellCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticGlycogen Synthase Kinase 3 betaHumansKidney NeoplasmsMaleMiceMice, NudeMiddle AgedBiomarkers, TumorGlycogen Synthase Kinase 3 betaProto-Oncogene Proteins c-aktSALL4 protein, humanTranscription FactorsVHL protein, humanVon Hippel-Lindau Tumor Suppressor ProteinAngiogenesisClear cell renal cell carcinomaSALL4TumorigenesisVHL mutation

Identifiers

PMID32513235
PMCPMC7278163
OpenAlexW3033444550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.